Cargando…
Treatment of rheumatoid arthritis with biological agents — as a typical and common immune-mediated inflammatory disease
Molecules involved in the disease process facilitated our understanding of pathogenesis of the disease with unknown etiology such as immune-mediated and inflammatory diseases. Moreover, the targeted therapies against the proposed molecular targets by biological agents provide enormous benefits to th...
Autor principal: | TAKEUCHI, Tsutomu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japan Academy
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743860/ https://www.ncbi.nlm.nih.gov/pubmed/29021510 http://dx.doi.org/10.2183/pjab.93.038 |
Ejemplares similares
-
Addendum to “Treatment of rheumatoid arthritis with biological agents — as a
typical and common immune-mediated inflammatory disease”
por: TAKEUCHI, Tsutomu
Publicado: (2018) -
Medicare expenditures for conventional and biologic disease modifying agents commonly used for treatment of rheumatoid arthritis
por: Dalal, Deepan S., et al.
Publicado: (2020) -
Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan
por: Mahlich, Jörg, et al.
Publicado: (2016) -
Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study
por: Lesuis, Nienke, et al.
Publicado: (2012) -
Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients
por: Saito, Shuntaro, et al.
Publicado: (2019)